ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type

The ALVAC-HIV clade B/AE and equivalent SIV-based/gp120 + Alum vaccines successfully decreased the risk of virus acquisition in humans and macaques. Here, we tested the efficacy of HIV clade B/C ALVAC/gp120 vaccine candidates + MF59 or different doses of Aluminum hydroxide (Alum) against SHIV-Cs of...

Descripción completa

Detalles Bibliográficos
Autores principales: Schifanella, Luca, Barnett, Susan W., Bissa, Massimiliano, Galli, Veronica, Doster, Melvin N., Vaccari, Monica, Tomaras, Georgia D., Shen, Xiaoying, Phogat, Sanjay, Pal, Ranajit, Montefiori, David C., LaBranche, Celia C., Rao, Mangala, Trinh, Hung V., Washington-Parks, Robyn, Liyanage, Namal P. M., Brown, Dallas R., Liang, Frank, Loré, Karin, Venzon, David J., Magnanelli, William, Metrinko, Michelle, Kramer, Josh, Breed, Matthew, Alter, Galit, Ruprecht, Ruth M., Franchini, Genoveffa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6890176/
https://www.ncbi.nlm.nih.gov/pubmed/31794588
http://dx.doi.org/10.1371/journal.ppat.1008121

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6890176/
https://www.ncbi.nlm.nih.gov/pubmed/31794588
http://dx.doi.org/10.1371/journal.ppat.1008121

Ejemplares similares